A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Vildagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 23 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2014 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.